What if you invested $1000 in ABBV on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 13 years, AbbVie Inc. has delivered an average annual return of 21.9%. The stock peaked in 2017 with a massive +60.6% gain, while investors faced a downturn in 2015 (-7.1%). Overall, the stock finished in the green 10 times out of 13 years.
Avg Return
+21.9%
Win Rate
77%
10W - 3L
Best
+60.6%
2017
Worst
-7.1%
2015
Performance Consistency
About AbbVie Inc.
Visit Website ↗AbbVie is a global, research-based biopharmaceutical company that originated as a spin-off of Abbott Laboratories. The company's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. They strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
Key Business Segments
Immunology
This segment includes products for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease.
Oncology
This segment develops and markets treatments for various types of cancer.
Neuroscience
This segment focuses on treatments for neurological and psychiatric disorders.
Eye Care
This segment provides products for a range of eye conditions.
Aesthetics
This segment includes the Allergan Aesthetics portfolio with products like Botox Cosmetic.
Key Innovations
- ✓Humira (adalimumab), a biologic medication used to treat a variety of autoimmune diseases.
- ✓Imbruvica (ibrutinib), a targeted therapy for certain types of cancer.
- ✓Venclexta (venetoclax), a medication for chronic lymphocytic leukemia.
Historical Milestones
AbbVie launches as an independent biopharmaceutical company, separating from Abbott Laboratories.
AbbVie acquires Pharmacyclics, expanding its oncology portfolio.
AbbVie announces its intention to acquire Allergan, the maker of Botox.
The acquisition of Allergan is completed.